
Lilly’s RNA Silencer Achieves Nearly 94% Reduction in Key Cardiovascular Biomarker
Lilly’s RNA Silencer Achieves Nearly 94% Reduction in Key Cardiovascular Biomarker Eli Lilly has made a groundbreaking advancement in cardiovascular medicine with its investigational small interfering RNA (siRNA) therapeutic, lepodisiran,…












